Needham & Company initiates coverage on Hi Tech Pharmacal Co (Nasdaq: HITK) with a Buy rating. PT $32.

Needham analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE